Sugi Predict

Sugi Predict / Compounds / SCHEMBL1630792

SCHEMBL1630792

SCHEMBL1630792

N#Cc1cc(F)c(Br)cc1F

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TRPV4 Q9HBA0 3/20 0.56
▸ CYP11B1 P15538 8/20 0.40
▸ CYP11B2 P19099 8/20 0.40
▸ KHK P50053 1/20 0.38
▸ KDM1A O60341 2/20 0.35
▸ KCNH2 Q12809 2/20 0.35
▸ KDM1B Q8NB78 1/20 0.35
▸ ESR1 P03372 1/20 0.33
▸ ESR2 Q92731 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ TTR P02766 1/20 0.33
▸ ALB P02768 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ EGLN2 Q96KS0 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31746624 1.00 TRPV4 (0.56) TRPV4CYP11B1CYP11B2KHKKDM1A
SCHEMBL14720036 0.91 TRPV4 (0.50) TRPV4CYP11B1CYP11B2KHKKDM1A
SCHEMBL29559549 0.91 TRPV4 (0.50) TRPV4CYP11B1CYP11B2KHKKDM1A
SCHEMBL23730336 0.88 TRPV4 (0.46) TRPV4CYP11B1CYP11B2KHKKDM1A
SCHEMBL27578806 0.86 TRPV4 (0.45) TRPV4CYP11B1CYP11B2KHKKDM1A
SCHEMBL10949641 0.86 TRPV4 (0.50) TRPV4CYP11B1CYP11B2KHKESR1
SCHEMBL15409386 0.86 TRPV4 (0.40) TRPV4CYP11B1CYP11B2KHKKDM1A
SCHEMBL6651303 0.84 TRPV4 (0.71) TRPV4CYP11B1CYP11B2KHK
SCHEMBL2713149 0.83 TRPV4 (0.46) TRPV4CYP11B1CYP11B2KHKESR1
SCHEMBL154197 0.82 TRPV4 (0.47) TRPV4CYP11B1CYP11B2EGLN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637461-B2 Compounds for the activation of AMPK PFIZER INC. (US) 2026-05-26 — — US disclosed
US-20260116879-A1 AZAINDOLE ROCK INHIBITORS AVICENNA BIOSCIENCES, INC. (US) 2026-04-30 — — US disclosed
EP-4725946-A1 IRAK4 DEGRADATION AGENT AND USE THEREOF Guangzhou Unirise Pharmaceutical Co., Ltd. (CN) 2026-04-15 — — EP disclosed
EP-4709720-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2026-03-18 — — EP disclosed
US-20260070917-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF DIFFERENTIATED THERAPEUTICS INC (US) 2026-03-12 — — US disclosed
EP-4694889-A1 COMPOUNDS AND METHODS FOR TREATING PROTEIN AGGREGATION DISEASES Acelot, Inc. (US) 2026-02-18 — — EP disclosed
WO-2025262295-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 DARK BLUE THERAPEUTICS LTD (GB) 2025-12-26 — — WO disclosed
EP-4667466-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 Dark Blue Therapeutics Ltd (GB) 2025-12-24 — — EP disclosed
EP-4665332-A2 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF Differentiated Therapeutics Inc (US) 2025-12-24 — — EP disclosed
US-12486248-B2 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH BAYER AKTIENGESELLSCHAFT (DE) 2025-12-02 — — US disclosed
EP-1263711-B1 NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES ASTRAZENECA AB (SE) 2004-12-15 — — EP disclosed
US-6743939-B2 NITRIC OXIDE SYNTHASE INHIBITORS; SUCH AS 4-CHLORO-2-(((1)-4-(METHYLAMINO)-1-PHENYLBUTYL)OXY)BENZONITRILE ASTRAZENECA AB (SE) 2004-06-01 — — US disclosed
EP-1263714-B1 NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES ASTRAZENECA AB (SE) 2004-04-28 — — EP disclosed
US-20030158185-A1 Novel use of phenylheteroakylamine derivatives ASTRAZENECA AB (SE) 2003-08-21 — — US disclosed
US-20030105161-A1 Novel phenylheteroalkylamine derivatives ASTRAZENECA AB (SE) 2003-06-05 — — US disclosed
CN-1411435-A Novel use of phenylheteroalkylamine derivatives ASTRAZENECA AB (SE) 2003-04-16 — — CN disclosed
EP-1263714-A1 NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES AstraZeneca AB (SE) 2002-12-11 — — EP disclosed
EP-1263711-A1 NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES AstraZeneca AB (SE) 2002-12-11 — — EP disclosed
WO-2001062704-A1 NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES ASTRAZENECA AB (SE) 2001-08-30 — — WO disclosed
WO-2001062713-A1 NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES ASTRAZENECA AB (SE) 2001-08-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637461-B2 Compounds for the activation of AMPK PRKAG1, PRKAB1, PRKAA1 TRPV4 3167/4885CYP11B1 391/4885CYP11B2 706/4885
US-20260116879-A1 AZAINDOLE ROCK INHIBITORS PRKG2, PRKG1, ROCK2 TRPV4 2256/4885CYP11B1 1176/4885CYP11B2 978/4885
US-12486248-B2 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH DHODH, DHPS, DPYD TRPV4 3901/4885CYP11B1 430/4885CYP11B2 271/4885
US-20030105161-A1 Novel phenylheteroalkylamine derivatives NOS1, CYP1A1, NOS2 TRPV4 665/4885CYP11B1 172/4885CYP11B2 231/4885
US-20260070917-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF CDK2, CCNK, CCNC TRPV4 4774/4885CYP11B1 1719/4885CYP11B2 1909/4885
US-20030158185-A1 Novel use of phenylheteroakylamine derivatives NOS1, XDH, NOS2 TRPV4 4055/4885CYP11B1 13/4885CYP11B2 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.